Discovery of Potent Protease Inhibitors for Covid-19 Treatment

Back to all technologies
Download as PDF
2020-GHOS-69088
Researchers at Purdue University have developed potent inhibitors for the SARS-CoV-2 protease enzyme 3CLpro. Covid-19, an infection caused by the SARS-CoV-2 virus, has led to an ongoing global pandemic. Currently, no effective drug treatment is available for Covid-19. To find a potential therapeutic for Covid-19, Purdue researchers discovered a series of novel noncovalent functionalized bis-amide derivatives that were previously reported to inhibit a SARS-CoV-2 enzyme, 3CLpro. These are modified versions of previous compounds to improve drug-like characteristics and antiviral properties against SARS-CoV-2. The inhibitors have been evaluated in immunocytochemical and cellular assays against Covid-19 infections. These compounds show promise to be an effective treatment for Covid-19 upon further evaluation on in vivo systems.

Advantages:
-Potent Covid-19 Antiviral Properties
-Improved Drug-Like Features

Potential Applications:
-Covid-19 Treatment
-Pandemic Control
-Pharmaceutical Research and Development

Technology Validation: The bis-amide compounds potently inhibited SARS-CoV-2 in in vitro studies and immunocytochemistry assays.
Mar 15, 2021
PCT-Gov. Funding
WO
(None)
(None)

Dec 1, 2020
Provisional-Gov. Funding
United States
(None)
(None)

May 15, 2020
Provisional-Gov. Funding
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org